Literature DB >> 12562869

Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen.

Kazuko Kobayashi1, Makoto Kishi, Tatsuya Atsumi, Maria L Bertolaccini, Hirofumi Makino, Nobuo Sakairi, Itaru Yamamoto, Tatsuji Yasuda, Munther A Khamashta, Graham R V Hughes, Takao Koike, Dennis R Voelker, Eiji Matsuura.   

Abstract

Beta2-glycoprotein I (beta2-GPI) is a major antigen for antiphospholipid antibodies (Abs, aPL) present in patients with antiphospholipid syndrome (APS). We recently reported (J. Lipid Res., 42: 697, 2001; J. Lipid Res., 43: 1486, 2002) that beta2-GPI specifically binds to Cu2+-oxidized LDL (oxLDL) and that the beta2-GPI ligands are omega-carboxylated 7-ketocholesteryl esters. In the present study, we demonstrate that oxLDL forms stable and nondissociable complexes with beta2-GPI in serum, and that high serum levels of the complexes are associated with arterial thrombosis in APS. A conjugated ketone function at the 7-position of cholesterol as well as the omega-carboxyl function of the beta2-GPI ligands was necessary for beta2-GPI binding. The ligand-mediated noncovalent interaction of beta2-GPI and oxLDL undergoes a temperature- and time-dependent conversion to much more stable but readily dissociable complexes in vitro at neutral pH. In contrast, stable and nondissociable beta2-GPI-oxLDL complexes were frequently detected in sera from patients with APS and/or systemic lupus erythematodes. Both the presence of beta2-GPI-oxLDL complexes and IgG Abs recognizing these complexes were strongly associated with arterial thrombosis. Further, these same Abs correlated with IgG immune complexes containing beta2-GPI or LDL. Thus, the beta2-GPI-oxLDL complexes acting as an autoantigen are closely associated with autoimmune-mediated atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12562869     DOI: 10.1194/jlr.M200329-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  39 in total

Review 1.  The antiphospholipid syndrome and atherosclerosis: clue to pathogenesis.

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

Review 2.  Intravenous immunoglobulin and atherosclerosis.

Authors:  Eiji Matsuura; Kazuko Kobayashi; Katsumi Inoue; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 3.  Antiphospholipid antibodies in rheumatoid arthritis: identifying the dominoes.

Authors:  Debbie A Gladd; Ewa Olech
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

Review 4.  Oxidized LDL: diversity, patterns of recognition, and pathophysiology.

Authors:  Irena Levitan; Suncica Volkov; Papasani V Subbaiah
Journal:  Antioxid Redox Signal       Date:  2010-07-01       Impact factor: 8.401

Review 5.  Immunomodulation of vascular diseases: atherosclerosis and autoimmunity.

Authors:  G-P Shi
Journal:  Eur J Vasc Endovasc Surg       Date:  2010-02-25       Impact factor: 7.069

Review 6.  Atherosclerosis in autoimmune diseases.

Authors:  Eiji Matsuura; Kazuko Kobayashi; Luis R Lopez
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

Review 7.  Immunogenic oxidized low-density lipoprotein/beta2-glycoprotein I complexes in the diagnostic management of atherosclerosis.

Authors:  Luis R Lopez; Kazuko Kobayashi; Yukana Matsunami; Eiji Matsuura
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 8.  Oxidative modification of LDL: its pathological role in atherosclerosis.

Authors:  Hiroyuki Itabe
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 9.  Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  Paul R J Ames; Annamaria Margarita; Jose Delgado Alves
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 10.  Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.

Authors:  Chary López-Pedrera; Maria Ángeles Aguirre; Nuria Barbarroja; Maria José Cuadrado
Journal:  J Biomed Biotechnol       Date:  2010-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.